

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: A61K 38/18, 31/557 // (A61K 38/18, 31:557) (A61K 38/18, 38:18, 31:557)	A1	(11) International Publication Number: WO 97/15319 (43) International Publication Date: 1 May 1997 (01.05.97)
(21) International Application Number: PCT/CN96/00698		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TI, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 23 October 1996 (23.10.96)		
(30) Priority Data: 60/005,790 23 October 1995 (23.10.95) US		
(60) Parent Application or Grant (63) Related by Continuation US Filed on 60/005,790 (CIP) 23 October 1995 (23.10.95)		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(71) Applicant (for all designated States except US): QUEEN'S UNIVERSITY AT KINGSTON [CA/CA]; Kingston, Ontario K7L 3N6 (CA).		
(72) Inventor; and (75) Inventor/Applicant (for US only): ANASTASSIADES, Tassos [CA/CA]; Queen's University, Etherington Hall, Kingston, Ontario K7L 3N6 (CA).		
(74) Agent: STAUFFS, Karen; McFadden, Fincham, Suite 606, 225 Metcalfe Street, Ottawa, Ontario K2P 1P9 (CA).		

(54) Title: METHOD AND PHARMACEUTICAL COMPOSITION FOR CHONDROSTIMULATION WITH A PROSTAGLANDIN (E.G. MISOPROSTOL) AND TGF-BETA, OPTIONALLY IN COMBINATION WITH IGF-1



(57) Abstract

A pharmaceutical composition comprising a prostaglandin having structure (I) and a compound chosen from the group consisting of TGF- β and IGF-1 wherein the prostaglandin, TGF- β and IGF-1 are present in an amount effective to stimulate the production of chondrocyte matrix or prevent the degeneration of chondrocyte matrix; and methods of stimulating the production, or preventing the degeneration, of chondrocyte matrix or cartilage matrix in a subject in need thereof by administration of a combination of the prostaglandin and TGF- β or a combination of the prostaglandin, TGF- β and IGF-1.

38+1


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: A61K 38/18, 31/557 // (A61K 38/18, 31:557) (A61K 38/18, 38:18, 31:557)	A1	(11) International Publication Number: WO 97/15319 (43) International Publication Date: 1 May 1997 (01.05.97)
(21) International Application Number: PCT/CA96/00698		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 23 October 1996 (23.10.96)		
(30) Priority Data: 60/005,790 23 October 1995 (23.10.95) US		
(60) Parent Application or Grant (63) Related by Continuation US 60/005,790 (CIP) Filed on 23 October 1995 (23.10.95)		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(71) Applicant (for all designated States except US): QUEEN'S UNIVERSITY AT KINGSTON [CA/CA]; Kingston, Ontario K7L 3N6 (CA).		
(72) Inventor; and (75) Inventor/Applicant (for US only): ANASTASSIADES, Tassos [CA/CA]; Queen's University, Etherington Hall, Kingston, Ontario K7L 3N6 (CA).		
(74) Agent: STAUFF, Karen; McFadden, Fincham, Suite 606, 225 Metcalfe Street, Ottawa, Ontario K2P 1P9 (CA).		

(54) Title: METHOD AND PHARMACEUTICAL COMPOSITION FOR CHONDROSTIMULATION WITH A PROSTAGLANDIN (E.G. MISOPROSTOL) AND TGF-BETA, OPTIONALLY IN COMBINATION WITH IGF-1



(57) Abstract

A pharmaceutical composition comprising a prostaglandin having structure (I) and a compound chosen from the group consisting of TGF- β and IGF-1 wherein the prostaglandin, TGF- β and IGF-1 are present in an amount effective to stimulate the production of chondrocyte matrix or prevent the degeneration of chondrocyte matrix; and methods of stimulating the production, or preventing the degeneration, of chondrocyte matrix or cartilage matrix in a subject in need thereof by administration of a combination of the prostaglandin and TGF- β or a combination of the prostaglandin, TGF- β and IGF-1.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BZ	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

TITLE

METHOD AND PHARMACEUTICAL COMPOSITION FOR CHONDROSTIMULATION WITH A PROSTAGLANDIN (E.G MISOPROSTOL) AND TGF-BETA, OPTIONALLY IN COMBINATION WITH IGF-1

BACKGROUND OF THE INVENTION

This invention relates to the use of certain prostaglandins in combination with certain growth factors to promote chondrocyte matrix or cartilage matrix production and thereby promote cartilage matrix synthesis and/or prevent the inhibition of cartilage matrix synthesis. In particular the invention relates to the use of a combination of prostaglandin, TGF- β and/or IGF-1 to stimulate chondrocyte matrix or cartilage matrix production and thereby promote cartilage matrix synthesis and/or prevent the inhibition of cartilage matrix synthesis.

Description of Related Art

- 15 This application is a continuation-in-part of U.S. Provisional Application No. 60/005,790, filed October 23, 1995, the contents of which are hereby incorporated by reference.
- 20 It has been recognized for over 2 decades that cartilage is capable of degradation and synthesis of

- 2 -

its extracellular matrix (Dingle, J.T. "The Role of Lysosomes in Connective Tissues Disease" in Hill, A.G., ed.) Modern Trends in Rheumatology, pp. 110-120, Butterworths 1966.) It is now recognized that repair 5 of cartilage damage is possible. (Nakata, et al. "The Injury and Repair of Human Articular Cartilage: A Morphological Study of 192 Cases of Osteoarthritis" J. Japan. Orthop. Ass. 1986, 60, 763-775.) In view of the recognition that cartilage damage, including damage 10 to the cartilage matrix, as well as the repair of such cartilage damage may be controllable, it would be desirable to find compounds which could be administered as pharmaceutical agents (medicaments) for the treatment of patients susceptible to or exhibiting 15 cartilage damage or inhibition of cartilage synthesis to inhibit such cartilage damage and/or enhance the repair of cartilage damage by overcoming the inhibition of cartilage matrix synthesis.

20 Non Steroidal Anti-Inflammatory Drugs ("NSAID") have long been used for the treatment of osteoarthritis ("OA") and rheumatoid arthritis ("RA") to provide relief from the pain associated with such diseases and to increase the range of movement in the patients with 25 such diseases. It has been found that some NSAIDs can inhibit cartilage matrix synthesis or promote cartilage damage. Thus, not only can cartilage damage arise due to such conditions as RA or OA, but also the pharmaceuticals indicated for treatment of such OA and 30 RA can also exhibit certain cartilage damaging properties.

It has been known for many years that articular cartilage chondrocytes retain their ability to 35 synthesize matrix components throughout life and exhibit the ability to take up sulphate and form new glycosaminoglycans ("GAGs"). GAGs are important

components of proteoglycans which are in turn key constituents of cartilage matrix. It would be desirable to identify compounds which can be used as a pharmaceutical product to enhance and/or promote the synthesis and repair of cartilage in a subject having damaged cartilage or otherwise in need of protection from cartilage degeneration.

It has been found that the catabolic action of the cytokine interleukin-1, ("IL-1" or "hrIL1 α ") plays an important role in inflammatory diseases and a role in cartilage damage and degeneration. Suppression of IL-1 production is possible using exogenous prostaglandin E (Bodger, et al. "Immuno Modulatory Approaches To The Treatment of Inflammation" in (Johns, W.F. ed.) Section I: Endocrinology, Immunology and Metabolic Disorders Annual Reports in Medicinal Chemistry, 1988, pp. 171-180 Academic Press Inc.; Kunkel, et al. "Arachidonic Acid Metabolites Regulate Interleukin 1 Production" Biochem. Biophys. Res. Commun. 1985, 128, 892-897; and Numo, et al. "Present Status and New Prospectives in Non Steroidal Anti-Inflammatory Drug Therapy" Scand. J. Rheumatol. 1987, Supplement 66, 75-83.) In view of the role of IL-1 in cartilage degeneration it is highly desirable to find a compound which could diminish the negative effects of IL-1 on cartilage matrix.

As is demonstrated herein, NSAID-induced inhibition of prostaglandin synthesis in mammalian chondrocytes can be suppressed by administration of a combination of certain prostaglandins, in particular misoprostol, with growth factors TGF- β and/or IGF-I. Moreover, the combination is shown to have a chondrostimulatory effect, promoting proteoglycan synthesis.


- 4 -

This invention therefore is directed to the use of certain prostaglandins in combination with growth factors to prevent cartilage matrix damage or cartilage matrix synthesis inhibition and to promote cartilage matrix synthesis in a patient susceptible to such cartilage matrix damage and such cartilage matrix synthesis inhibition.

SUMMARY OF THE INVENTION

10

This invention provides a pharmaceutical composition comprising a prostaglandin having the structure:



15

and a compound chosen from the group consisting of TGF- β and IGF-1 wherein the prostaglandin, TGF- β and IGF-1 are present in an amount effective to promote the production of chondrocyte matrix or prevent the degeneration of chondrocyte matrix. The invention also provides a method of stimulating the production of, or preventing the degeneration of, cartilage matrix in a subject in need thereof.

25 Brief Description of the Figures

Figure 1 shows a typical profile for the cellulose acetate electrophoresis of radiolabelled GAG. Each bar represents average of six values of ^{35}S -radioactivity determined at a given distance from the origin for GAG samples isolated from the media of a duplicate set of cultures. The error bars represent standard deviation.

- 5 -

Figure 2 shows the effects of acetylsalicylic acid ("ASA") on the basal and TGF- β -stimulated synthesis of GAG by bovine articular chondrocytes ("BAC") cultures: "C" represents control cultures with no treatment; 5 "ASA" represents cultures treated with 250 $\mu\text{g}/\text{ml}$ ASA; "TGF" represents cultures treated with 10 ng/ml TGF- β ; "ASA+TGF" represents cultures treated with both 250 $\mu\text{g}/\text{ml}$ ASA and 10 ng/ml TGF- β . Each bar represents average value of six determinations of ^{35}S -incorporation 10 into GAG for GAG samples isolated from media of a duplicate set of cultures. The error bars represent standard deviation.

Figure 3 shows the effects of ASA and misoprostol, 15 separately and in combination, on GAG synthesis by BAC cultures. "C" represents control cultures without any treatment; "ASA" represents cultures treated with 250 $\mu\text{g}/\text{ml}$ ASA; "MP" represents cultures treated with 80 ng/ml misoprostol; "ASA+MP" represents cultures treated 20 with both 250 $\mu\text{g}/\text{ml}$ ASA and 80 ng/ml misoprostol.

Figure 4 shows the effects of TGF- β , ASA and misoprostol, separately and in various combinations, on GAG synthesis by BAC cultures. "C" represents control 25 cultures; "TGF" represents cultures treated with 10 ng/ml TGF- β ; "TGF+ASA" represents cultures treated with 10 ng/ml TGF- β and 250 $\mu\text{g}/\text{ml}$ ASA; "TGF+MP" represents cultures treated with 10 ng/ml TGF- β and 80 ng/ml misoprostol; "TGF+ASA+MP" represents cultures treated 30 with 10 ng/ml TGF- β , 250 $\mu\text{g}/\text{ml}$ ASA and 80 ng/ml misoprostol simultaneously.

Figure 5 shows the effects of ASA on basal and IGF-I-stimulated GAG synthesis by BAC cultures. "C" 35 represents control cultures; "ASA" represents cultures treated with 250 $\mu\text{g}/\text{ml}$ ASA; "IGF" represents cultures treated with 150 ng/ml IGF-I; "ASA+IGF" represents


- 6 -

cultures treated with both 250 µg/ml ASA and 150 ng/ml IGF-1.

Figure 6 shows the effects of IGF-1, ASA and 5 misoprostol, separately and in various combinations, on GAG synthesis by BAC cultures. "C" represents control cultures; "IGF" represents cultures treated with 150 ng/ml IGF-1; "IGF+ASA" represents cultures treated with 150 ng/ml IGF-1 and 250 µg/ml ASA; "IGF+MP" represents 10 cultures treated with 150 ng/ml IGF-1 and 80 ng/ml misoprostol; "IGF+ASA+MP" represents cultures treated with 150 ng/ml IGF-1, 250 µg/ml ASA and 80 ng/ml misoprostol simultaneously.

15 Detailed Description of the Invention

The invention provides a pharmaceutical composition comprising a prostaglandin having the structure




20

and a compound chosen from the group consisting of TGF-
β and IGF-1 wherein the prostaglandin, TGF-β and IGF-1
are present in an amount effective to promote the
25 production of chondrocyte matrix or prevent the
degeneration of chondrocyte matrix. For the purposes
of this invention the terms "chondrocyte matrix" and
"cartilage matrix" are used interchangeably. In one
embodiment, the pharmaceutical composition comprises a
30 prostaglandin and TGF-β. In a separate embodiment, the
pharmaceutical composition comprises a prostaglandin,
TGF-β and IGF-1. The pharmaceutical composition can be

used to stimulate production of the chondrocyte matrix and thereby promote cartilage matrix synthesis or inhibit cartilage matrix degeneration in a subject susceptible to cartilage matrix degeneration or 5 cartilage matrix synthesis inhibition.

The invention also provides a method of treating a subject which comprises administering a pharmaceutical composition comprising a prostaglandin having the 10 structure:



and a compound chosen from the group consisting of TGF-
15 β and IGF-1 wherein the prostaglandin, TGF- β and IGF-1 are present in an amount effective to promote the production of chondrocyte matrix. In one embodiment, the method comprises administration of a pharmaceutical composition which comprises a prostaglandin and TGF- β .

20 In a separate embodiment, the method comprises administration of a pharmaceutical composition which comprises a prostaglandin, TGF- β and IGF-1.

Subjects to which the pharmaceutical compositions of
25 this invention would be administered include all vertebrates, in particular mammals. In a preferred embodiment the subject would be human. The methods of this invention are practiced by administering to a subject having damaged cartilage or otherwise in need 30 of protection from cartilage degeneration an effective chondrocyte matrix growth-stimulating amount of one of the pharmaceutical compositions described above. In

addition, the method can be practice by co-administration of the compounds which form the above-described pharmaceutical compositions in combination, each in the form of a separate pharmaceutical composition.

The prostaglandin compounds, and their preparation are described in U.S. Patent 3,965,143 and 4,060,691. The prostaglandin compounds herein are commercially available under the USAN (United States Adopted Name) misoprostol as a pharmaceutical which has been accepted for use in the treatment of NSAID induced gastric and gastrointestinal ulcers in many countries, including the United States, and which is commercially available by prescription in such countries. Misoprostol, ((+/-)-methyl-11 α , 16-dihydroxy-16-methyl-9-oxoprostaglandin E₁ (PGE₁) and is sold by G.D. Searle & Co. (Chicago, Ill.) under the name CYTOTEC. Examples of nonsteroidal anti-inflammatory drugs include, but are not limited to, aspirin, ibuprofen and naproxen. NSAIDs are known to contribute to degradation of articular cartilage and/or articular cartilage matrix.

Transforming growth factor- β (TGF- β) is a multipotent dimeric polypeptide growth factor that functions as an inducer during vertebrate development. Depending on target cell type, TGF- β may function as a growth inhibitor or as a growth stimulator. It belongs to a protein superfamily whose members share structural, and presumably functional, features. TGF- β is reviewed in Massagué, Ann. Rev. Cell Biol., Vol. 6, page 597 (1990), the disclosure of which is hereby incorporated by reference.) Virtually all mammalian cells have TGF- β receptors that control a variety of functions depending on cell lineage.

Insulin-like growth factor-I (IGF-I) is a polypeptide growth factor belonging to the diverse insulin protein superfamily (Blundell and Humbel, Nature, Vol. 287, pages 781-787, the disclosure of which is hereby incorporated by reference. Like insulin, IGF-I binds to a cell surface receptor tyrosine kinase, albeit a different receptor than the insulin receptor.

The following patents are incorporated by reference into this specification to more completely describe the invention: U.S. Patent No. 5,324,639 (Brierley et al.) (teaches recombinant techniques for the production of IGF-1); U.S. Patent No. 4,886,747 (Derynck et al.) (teaches recombinant techniques for the production of TGF- β); U.S. Patent No. 5,210,074 (Nakanishi et al.) (teaches a method for preparing a dried composition of IGF-1); U.S. Patent No. 4,983,581 (Antoniades et al.) (teaches the preparation of pharmaceutical compositions containing TGF- β and IGF-1); U.S. Patent No. 4,929,442 (Powell) (teaches the preparation of pharmaceutical compositions containing TGF- β); U.S. Patent Nos. 5,444,045 (Francis et al.) and 5,168,102 (Cogburn) (teach the administration of compositions comprising IGF-1 to birds); U.S. Patent No. 5,444,047 (DiPasquale) (teaches the therapeutic application of IGF-1).

By virtue of the activity of the compounds described herein in stimulating chondrocyte matrix production, and thereby promoting cartilage growth or inhibiting cartilage damage, the compounds are useful in inhibiting cartilage damage which may arise as a result of a natural condition such as osteoarthritis or rheumatoid arthritis or a provoked condition such as can occur by administration of NSAID therapy. A physician or veterinarian of ordinary skill can determine whether a subject exhibits or is susceptible

- 10 -

to articular degeneration and associated cartilage damage.

The compounds can be administered in such oral dosage forms as tablets, capsules, soft gels, pills, powders, granules, elixirs, or syrups. The compounds can also be administered intravascularly, intraperitoneally, subcutaneously, intramuscularly, intraarticularly, or topically, using forms known to the pharmaceutical art.

Moreover, they can be administered rectally or vaginally, in such forms as suppositories or bougies.

For the orally administered pharmaceutical compositions, the prostaglandin will typically be administered in a mixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as "carrier" materials) suitably selected with respect to the intended form of administration. That is, oral tablets, capsules, soft gels, elixirs, syrups, drops and the like, and consistent with conventional pharmaceutical practices.

For example, for oral administration in the form of tablets or capsules, a therapeutically effective amount of one or more compounds of the present invention can be combined with any oral non-toxic pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium phosphate, mannitol, and the like, or various combinations thereof.

For oral administration in liquid forms, such soft gels, elixirs, syrups, drops and the like, a therapeutically effective amount of an active combination of prostaglandin, TGF- β and IGF-1 can be combined with any oral non-toxic pharmaceutically acceptable inert carrier such as water, saline,

- 11 -

ethanol, polyethylene glycol, propylene glycol, corn oil, cottonseed oil, peanut oil; sesame oil, benzyl alcohol, various buffers, and the like, or various combinations thereof. Moreover, when desired or 5 necessary, suitable binders, lubricants, disintegrating agents, and grilling agents can also be incorporated in the mixture. Suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, 10 carboxymethylcellulose, polyethylene glycol, and waxes, or combinations thereof. Lubricants for use in these dosage forms include boric acid, sodium benzoate, sodium acetate, sodium chloride, and the like, or combinations thereof. Disintegrators include, without 15 limitation, starch, methylcellulose, agar, bentonite, agar gum, and the like, or combinations thereof. Sweetening and flavoring agents and preservatives can also be included where appropriate. In the practice of this invention, oral administration would require the 20 use of carriers or other components in the pharmaceutical composition which would protect the growth factors from digestion in a subject's gastrointestinal tract.

25 For intravascular, intraarticular, intraperitoneal, subcutaneous, or intramuscular administration, one or more compounds of the present invention can be combined with a suitable carrier such as water, saline, aqueous dextrose, and the like. It is also anticipated that 30 the claimed pharmaceutical compositions could be formulated for topical administration, wherein therapeutically effective amounts of one or more the compounds can be combined with pharmaceutically acceptable creams, oil, waxes, gels, including oil-based and water-based gels, and the like.

- 12 -

Regardless of the route of administration selected, the prostaglandins herein are formulated in a pharmaceutically acceptable dosage form by conventional methods known to those skilled in the art.

5

Regardless of the route of administration selected, a non-toxic therapeutically effective quantity of one or more compounds is employed in the treatment. The dosage regimen for stimulating chondrocyte matrix production and thereby preventing inhibition of cartilage synthesis or inhibiting cartilage damage is selected in accordance with a variety of factors, including the type, age, weight, sex, and medical condition of the subject, the severity of the cartilage damage, the route of administration, and the particular composition, including the biological activity of the compounds in the composition, employed in the therapeutic regimen. A physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent or arrest the progress of the condition. In so proceeding, the physician or veterinarian can employ relatively low doses at first and subsequently increase the dose until a maximum response is obtained.

25

The compounds herein can be combined with a variety of pharmaceutically acceptable carriers and administered in a variety of dosage forms such as pills, tablets and pre-formulated liquids as well as sustained dosage forms.

A particularly preferred stable solid dosage form of the compound (+/-) methyl 11 α ,16-dihydroxy-16-methyl-9-oxoprost-13E-en-1-oate is a stabilized formulation as disclosed in U.S. Patent 4,301,146. The formulation disclosed in the patent is the commercially available stabilized formulation for misoprostol. The

- 13 -

commercially available misoprostol is stabilized with hydroxypropylmethylcellulose (HPMC) as set forth in the patent. For the purposes of the use of misoprostol, the commercially available misoprostol is acceptable 5 for use in the invention herein.

The following example is provided to further illustrate the invention. It is not intended, and should not be interpreted, to limit the scope of the invention which 10 is defined in the claims which follow thereafter.

Example 1

Materials. ASA and ^{35}S -sulfate were obtained from ICN 15 (Costa Mesa, California). Misoprostol was provided by Searle (Skokie, Illinois). Porcine platelet TGF- β (referred to hereafter as TGF- β) and human recombinant IGF-1 were from R and D Systems. CMRL-1969 medium was from Connaught Laboratories (Willowdale, Ontario, 20 Canada). Penicillin-streptomycin and fetal bovine serum (FBS) were obtained from Gibco. Cetylpyridinium chloride (CPC), chondroitin sulfate, hyaluronic acid and papain were from Sigma Chemical Co (St. Louis, Missouri).

25

Isolation and Culture of Chondrocytes. Chondrocytes were released by collagenase digestion from minces of BAC obtained aseptically from the ankle joints of 1-2 year old bovines within 2-4 hours of slaughter, by the 30 method described in Howard, S., Anastassiades, T.P., J. Rheumatol., (1993) Vol. 20, pages 2083-2094; and Anthanassiades A., Anastassiades, T.P. In vitro Cell Develop. Biol., (1994) Vol. 30A, pages 510-511. The released cells were suspended in CMRL-1969 medium 35 containing 20% FBS and 2% penicillin-streptomycin (growth medium) and seeded into 6-well (35 mm diameter) culture plates (Falcon) containing 2 ml of growth

- 14 -

medium to achieve a final density of 300,000-500,000 cells/well. The cells were grown to confluence with refeeding every alternate day with the growth medium. At confluence, the FBS concentration in the medium was 5 stepped-down gradually to 5% by first replacing the growth medium with CMRL-1969 medium containing 10% FBS and 2% penicillin-streptomycin, allowing the cells to adapt for 2 days, and then replacing the latter medium with CMRL-1969 medium containing 5% FBS and 2% 10 penicillin-streptomycin (incubation medium).

Treatment and Radiolabelling of Cultures. After allowing the cultures to adapt for 2 days in the incubation medium, the medium was removed and replaced 15 with 2 ml of fresh incubation medium. Following addition of various test agents, dissolved in appropriate solvents, separately and in different combinations, to triplicate sets of culture wells, the cultures were pre-incubated for 2 days. ASA, 20 misoprostol and TGF- β were dissolved in distilled water, absolute ethanol and 4 mM HCl/1mg/ml BSA, respectively, and added to the culture wells in appropriate, small volumes to give final concentrations of 10 ng/ml TGF- β , 250 μ g/ml ASA and 80 ng/ml 25 misoprostol. IGF-1 was dissolved directly in the incubation medium prior to its addition to the cultures. Equivalent volumes of ethanol and 4 mM HCl/1mg/ml BSA were added to control cultures and to cultures lacking either solvent addition. The 30 polypeptide growth factors were added at optimal concentrations for the stimulation of GAG synthesis in the BAC system. The optimal stimulatory concentration for TGF- β was 10 ng/ml (as reported in Howard, S. et al. J. Rheumatol., (1993) above) and for IGF-1 it was 35 150 ng/ml (personal observations).

After pre-incubation, the media containing the test agents were removed from the cultures and replaced with fresh incubation medium and the appropriate test agents at the same concentrations as during pre-incubation.

5 ^{35}S -sulfate was then added to all culture wells to achieve a final concentration of 10 $\mu\text{Ci}/\text{ml}$ and the cultures incubated for 2 more days. In these experiments a stabilizer for misoprostol, such as hydroxypropylmethyl cellulose (HPMC) noted above was
10 not added to the cultures.

Cell Counting. At the end of incubation, the radiolabelled incubation medium was removed and stored at -20°C , the cells rinsed with phosphate buffered
15 saline (PBS) and detached by incubation with 0.25% trypsin at 37°C . Trypsinization was terminated by adding the growth medium, containing 20% FBS, and the cells counted on a Coulter counter, after dilution of the released cells in Hematall isotonic diluent.

20

Determination of ^{35}S Incorporation into GAG. After supplementing the culture medium with hyaluronic acid and chondroitin sulfate as the carrier GAGs, the newly synthesized, radiolabelled GAG were isolated by
25 digestion of protein core of the peptidoglycans with papain followed by precipitation of the released GAG with CPC and ethanol using the method described in Hronowski, L., Anastassiades, T.P., J. Biol. Chem., (1980) Vol. 255, pages 9210-9217. The final GAG
30 precipitate was dissolved in 200 μl of distilled water and an aliquot electrophoresed on a cellulose acetate strip using the method described in Hronowski, L.,
Anastassiades, T.P., Anal. Biochem., (1979) Vol. 93, pages 60-72. After staining, destaining and drying of
35 the electrophoresed strip, the strip was cut into 1 cm sections and the radioactivity in each section determined by scintillation counting in Betamax (ICN).

- 16 -

A typical electrophoretic profile of the isolated, radiolabelled GAG is shown in Figure 1. Virtually all of the radioactivity incorporated from ^{35}S -sulfate into the GAGs precipitated by CPC and subjected to 5 electrophoresis was identified as chondroitin sulfate by digestion with the specific chondroitinases ABC and AC using the method described in Howard, S. et al. J. Rheumatol., (1993), and Hronoski et al. Anal. Biochem., (1979) above. Hereafter, the incorporated 10 ^{35}S -radioactivity co-migrating with carrier chondroitin sulfate (generally bands number 7 and 8, as shown in Figure 1) will be designated to reflect net synthesis of the sulfated GAG, accumulating into the culture medium over the 2 day period of radio labelling of the 15 BAC cultures (Figures 2-6).

RESULTS. The BAC system is particularly suitable for assessing effects of growth factors and drugs since it does not present a tissue permeability problem for 20 these substances and has better reproducibility among replicate cultures than the slice or organ culture systems. See, Anthanassiades A., et al., In vitro Cell Develop. Biol., (1994) above.

25 Addition of ASA (250 $\mu\text{g/ml}$) alone to BAC cultures had no significant effect on basal GAG synthesis (Figure 2). While the addition of TGF- β (10 ng/ml) alone stimulated GAG synthesis by 158%, addition of TGF- β together with ASA suppressed this stimulation to 48% 30 above the control value (Figure 2). The addition of misoprostol (80 ng/ml) alone to the cultures caused 135% stimulation of GAG synthesis, whereas addition of misoprostol in combination with ASA reduced the misoprostol-induced stimulation of GAG synthesis to 49% 35 % (Figure 3). The addition of misoprostol in combination with TGF- β showed 142% greater stimulation of GAG synthesis than the sum of the stimulatory


- 17 -

effects observed with misoprostol and TGF- β separately (Figure 4). Also, addition of misoprostol together with TGF- β almost completely abolished the suppressive effects of ASA on the stimulation of GAG synthesis by 5 either misoprostol or TGF- β alone.

IGF-1 (150 ng/ml) stimulated GAG synthesis by 78%, but ASA showed no significant effect on this stimulation (Figure 5). This observation would suggest that the 10 stimulatory effect of IGF-1 may not be through a prostaglandin synthetic pathway, since ASA did not affect IGF-1-dependent stimulation. Also, the individual stimulatory effects on GAG synthesis of IGF-1 and misoprostol (when these agents were added to 15 the cultures separately) were 93% greater than the stimulatory effect of the combined treatment (Figure 6). However, the use of IGF-1 in combination with a prostaglandin and TGF- β is nonetheless warranted in view of these results.

What is claimed is:


1. A pharmaceutical composition comprising a prostaglandin having the structure:



and TGF- β , wherein the prostaglandin and TGF- β are present in an amount effective to stimulate the production of chondrocyte matrix or prevent the degeneration of chondrocyte matrix.

2. The pharmaceutical composition of claim 1 further comprising IGF-1, wherein the prostaglandin, TGF- β and IGF-1 are present in an amount effective to stimulate the production of chondrocyte matrix or prevent the degeneration of chondrocyte matrix.

3. A method for treating a subject which comprises administering to the subject a pharmaceutical composition comprising a prostaglandin having the structure:




and TGF- β , wherein the prostaglandin and TGF- β are present in an amount effective to stimulate the

- 19 -

production of chondrocyte matrix or prevent the degeneration of chondrocyte matrix.


4. The method of claim 3 wherein the pharmaceutical composition comprises the prostaglandin, TGF- β and IGF-1 are present in an amount effective to stimulate the production of chondrocyte matrix or prevent the degeneration of chondrocyte matrix.

5. A method for treating a subject which comprises administering to the subject, in combination, (a) a pharmaceutical composition comprising a prostaglandin having the structure:



and (b) a pharmaceutical composition comprising TGF- β ; wherein the prostaglandin and TGF- β are administered in an amount effective to collectively stimulate the production of chondrocyte matrix or prevent the degeneration of chondrocyte matrix.

6. A method for treating a subject which comprises administering to the subject in combination, (a) a pharmaceutical composition comprising a prostaglandin having the structure:




(b) a pharmaceutical composition comprising TGF- β and
(c) a pharmaceutical composition comprising IGF-1;
wherein the prostaglandin, TGF- β and IGF-1 are
administered in an amount effective to collectively
stimulate the production of chondrocyte matrix or
prevent the degeneration of chondrocyte matrix.

7. A method for inhibiting chondrocyte matrix damage
in a subject susceptible to such damage, the method
comprising administering to the subject the
pharmaceutical composition of claim 1.

8. A method for inhibiting chondrocyte matrix damage
in a subject susceptible to such damage, the method
comprising administering to the subject the
pharmaceutical composition of claim 2.

9. A method for inhibiting chondrocyte matrix damage
in a subject susceptible to such damage, the method
comprising administering to the subject, in
combination, (a) a pharmaceutical composition
comprising a prostaglandin having the structure:



- 21 -


and (b) a pharmaceutical composition comprising TGF- β ; wherein the prostaglandin and TGF- β are administered in an amount effective to stimulate the production of chondrocyte matrix in the subject.

10. The method of claim 9 which further comprises administering to the subject a pharmaceutical composition comprising IGF-1, wherein the prostaglandin, TGF- β and IGF-1 are administered in an amount effective to collectively stimulate the production of chondrocyte matrix in the subject.

11. A method for stimulating the production of chondrocyte matrix in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition of claim 1.

12. A method for stimulating the production of chondrocyte matrix in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition of claim 2.

13. A method for stimulating the production of chondrocyte matrix in a subject in need thereof, the method comprising administering to the subject, in combination, (a) a pharmaceutical composition comprising a prostaglandin having the structure:



and (b) a pharmaceutical composition comprising TGF- β ; wherein the prostaglandin and TGF- β are administered in

- 22 -


an amount effective to stimulate the production of chondrocyte matrix in the subject.

14. The method of claim 13 which further comprises administering to the subject a pharmaceutical composition comprising IGF-1, wherein the prostaglandin, TGF- β and IGF-1 are administered in an amount effective to collectively stimulate the production of chondrocyte matrix in the subject.

15. A method for inhibiting a damaging effect of a non-steroidal anti-inflammatory drug on chondrocyte matrix in a subject susceptible to such damaging effect, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 1.

16. A method for inhibiting a damaging effect of a non-steroidal anti-inflammatory drug on chondrocyte matrix in a subject susceptible to such damaging effect, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 2.

17. A method for inhibiting a damaging effect of a non-steroidal anti-inflammatory drug on chondrocyte matrix in a subject susceptible to such damaging effect, the method comprising administering to the subject, in combination, (a) a pharmaceutical composition comprising a prostaglandin having the structure:



and (b) a pharmaceutical composition comprising TGF- β ; wherein the prostaglandin and TGF- β are administered in an amount effective to stimulate the production of chondrocyte matrix in the subject.

18. The method of claim 17 which further comprises administering to the subject a pharmaceutical composition comprising IGF-1, wherein the prostaglandin, TGF- β and IGF-1 are administered in an amount effective to stimulate the production of chondrocyte matrix in the subject.


19. A method for inhibiting the damaging effect of IL-1 on chondrocyte matrix in a subject susceptible to such damaging effect, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 1.

20. A method for inhibiting the damaging effect of IL-1 on chondrocyte matrix in a subject susceptible to such damaging effect, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 2.

21. A method for inhibiting a damaging effect of IL-1 on chondrocyte matrix in a subject susceptible to such damaging effect, the method comprising administering to the subject, in combination, (a) a pharmaceutical

- 24 -

composition comprising a prostaglandin having the structure:




and (b) a pharmaceutical composition comprising TGF- β ; wherein the prostaglandin and TGF- β are administered in an amount effective to stimulate the production of chondrocyte matrix in the subject.

22. The method of claim 21 which further comprises administering to the subject a pharmaceutical composition comprising IGF-1, wherein the prostaglandin, TGF- β and IGF-1 are administered in an amount effective to stimulate the production of chondrocyte matrix in the subject.


1/6

FIGURE 1



2/6

FIGURE 2



3/6

FIGURE 3





FIGURE 4



5/6

FIGURE 5





FIGURE 6



INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 96/00698

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K38/18 A61K31/557 // (A61K38/18, 31:557), (A61K38/18, 38:18,
31:557)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ARTHRITIS & RHEUMATISM, vol. 38, no. 9 suppl., 21 October 1995, page s161 XP002027218 R.K. CHOPRA ET AL.: "Marked suppression of the TGF-beta-induced stimulation of proteoglycan (PG) synthesis by aspirin and its reversal by prostaglandin (PG)E-1 analogue misoprostol (MP) in cultures of bovine articular chondrocytes (BAC)" see abstract	1,3,5,7, 9,11,13, 15,17
Y	EP 0 445 948 A (SEARLE & CO) 11 September 1991 see the whole document see claims 1-9	1-22
	---	1-22
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

1

Date of the actual completion of the international search

10 March 1997

Date of mailing of the international search report

21.03.97

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patendaan 2
NL - 2230 HV Rijswijk
Tel. (+31-70) 340-2040, Telex 31 651 epo nl
Fax (+31-70) 340-3016

Authorized officer

Stierman, B

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 96/00698

C/(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	J RHEUMATOL, vol. 17, no. suppl. 20, February 1990, pages 50-53, XP002027219 P.A. NICHOLSON: "Recent advances in defining the role of misoprostol in rheumatology" see the whole document ----	1-22
Y	J LIPID MEDIAT, vol. 6, no. 1-3, 1993, pages 303-312, XP002027220 J.T. DINGLE : "Prostaglandins in human cartilage metabolism" see the whole document ----	1-22
Y	BIOCHEM BIOPHYS RES COMMUN, vol. 162, no. 1, 1989, pages 144-150, XP002027221 H.J. ANDREWS ET AL.: "Transforming growth factor-beta causes partial inhibition of interleukin 1-stimulated cartilage degradation in vitro" see the whole document ----	1-22
Y	MED J KINKI UNIV, vol. 18, no. 2, 1993, pages 241-252, XP002027222 K. OHTANI : "The role of transforming growth factor-beta in keratan sulfate metabolism in rabbit articular chondrocytes" see abstract ----	1-22
Y	EP 0 434 625 A (CIBA GEIGY AG) 26 June 1991 see the whole document ----	2,4,6,8, 10,12, 14,16, 18,20,22
Y	ARCH ORTHOP TRAUMA SURG, vol. 114, no. 1, 1994, pages 43-48, XP002027223 J. NEIDEL ET AL.: "Insulin-like growth factor I accelerates recovery of articular cartilage proteoglycan synthesis in culture after inhibition by interleukin 1" see the whole document -----	2,4,6,8, 10,12, 14,16, 18,20,22
1		

INTERNATIONAL SEARCH REPORT

In national application No. -
PCT/CA 96/00698

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Not: because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 3-22 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Not: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Not: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No	
PCT/CA 96/00698	

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0445948 A	11-09-91	GB 2241436 A AU 635615 B AU 7137791 A CA 2037088 A JP 6227985 A	04-09-91 25-03-93 29-08-91 29-08-91 16-08-94
EP 0434625 A	26-06-91	AT 121296 T AU 641966 B AU 6824790 A CA 2032859 A DE 69018799 D DE 69018799 T ES 2071080 T IE 67510 B IL 96711 A JP 4210648 A	15-05-95 07-10-93 27-06-91 23-06-91 24-05-95 21-09-95 16-06-95 03-04-96 19-01-96 31-07-92

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.